Scientific Library
PARP and Top1 inhibitors most beneficial in endonuclease-deficient cancer cells
The synergistic combination of Poly(ADP-ribose) polymerases (PARP) and Topoisomerase I (Top1) inhibitors most beneficial on endonuclease-deficient cancer cells in cancer therapies ?
This is one of the
EndoG and ATM cell cycle checkpoint in Leukemogenesis
In a recent publication, Gole B. and Baumann C. demonstrate the role of the apoptotic nuclease EndoG in Mixed-Lineage Leukemia breakpoint cluster region (MLLbcr) destabilisation leading to MLL gene
ATM or DNA-PKcs inhibitors synthetically lethal in BRCA- cells
Several lines of evidence show that synthetic lethal interactions targeting DNA repair pathways may have clinical applications in cancer therapy. In a recent paper, Albarakati et al. demonstrate that
Biological samples solutions: the chalenges of in vitro models
Access this on-demand webinar to discover how Tebubio leverages its expertise to help you source high-quality human biological samples, enabling you to develop the in-vitro model best suited to your research